Dr. Christopher H. Gibbons, Senior Scientific Advisor of CND Life Sciences, was recently interviewed in a Medscape Neurology story titled “Skin Testing May Help Detect Movement Disorders.”
In the interview, Dr. Gibbons describes research he presented at this year’s American Academy of Neurology examining how phosphorylated alpha-synuclein (p-syn) testing can contribute to the diagnosis and management of synucleinopathies. In the study, a panel of physicians reviewed the medical histories of patients with suspected synucleinopathies and determined if they had a probable or possible diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or undifferentiated synucleinopathy. P-syn testing was performed using the Syn-One Test®, and the results were compared to the physician panel’s determination.
Dr. Gibbons also discusses the types of cases where clinicians might consider using the Syn-One Test in their practice to help clarify the diagnosis and management of a synucleinopathy and how testing for p-syn can contribute to the search for disease-modifying therapies.